四环医药附属公司吡洛西利临床研究成果登《Nature Communications》
4月10日，四环医药（00460）发布公告，宣布其非全资附属公司轩竹生物研发的创新药吡洛西利在联合氟维司群治疗HR+/HER2-晚期乳腺癌的临床III期研究（BRIGHT-2）的期中分析结果已正式刊登于顶级期刊Nature子刊《Nature Communications》。该研究聚焦于中国乳腺癌患者，招募了305例经内分泌治疗后进展的患者，其中中位年龄为55岁，37.0%为绝经前，68.2%有内脏转移。
在中位随访8.7个月时，吡洛西利联合氟维司群的中位无进展生存期（PFS）达到12.94个月，明显高于氟维司群组的7.29个月。各亚组患者均表现出PFS获益，尤其是内分泌原发耐药和单纯骨转移患者的风险降低显著，联合组的客观缓解率为39.7%。这一成果进一步巩固了吡洛西利在CDK4/6抑制剂中的领先地位，并为全球乳腺癌患者提供了更有效的治疗方案。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10